Pharmacologic management of primary sclerosing cholangitis: what’s in the pipeline?

References

• Bambha K, Kim WR, Talwalkar J, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology. 2003;125(5):1364–1369.
   PubMed Web of Science ®Google Scholar
• Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012;56(5):1181–1188.
   PubMed Web of Science ®Google Scholar
• Toy E, Balasubramanian S, Selmi C, et al. The prevalence, incidence and natural history of primary sclerosing cholangitis in an ethnically diverse population. BMC Gastroenterol. 2011;11:83.
   PubMed Web of Science ®Google Scholar
• Weismuller TJ, Trivedi PJ, Bergquist A, et al. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology. 2017;152(8):1975–1984.e1978.
   PubMed Web of Science ®Google Scholar
• Lunder AK, Hov JR, Borthne A, et al. Prevalence of sclerosing cholangitis detected by magnetic resonance cholangiography in patients with long-term inflammatory bowel disease. Gastroenterology. 2016;151(4):660–669.e664.
   PubMed Web of Science ®Google Scholar
• Kim WR, Therneau TM, Wiesner RH, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc. 2000;75(7):688–694.
   PubMed Web of Science ®Google Scholar
• Olsson R, Danielsson A, Jarnerot G, et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology. 1991;100(5 Pt 1):1319–1323.
   PubMed Web of Science ®Google Scholar
• Schrumpf E, Elgjo K, Fausa O, et al. Sclerosing cholangitis in ulcerative colitis. Scand J Gastroenterol. 1980;15(6):689–697.
   PubMed Web of Science ®Google Scholar
• Gulamhusein AF, Eaton JE, Tabibian JH, et al. Duration of inflammatory bowel disease is associated with increased risk of cholangiocarcinoma in patients with primary sclerosing cholangitis and IBD. Am J Gastroenterol. 2016;111(5):705–711.
   PubMed Web of Science ®Google Scholar
• Tabibian JH, Ali AH, Lindor KD. Primary sclerosing cholangitis, part 1: epidemiology, etiopathogenesis, clinical features, and treatment. Gastroenterol Hepatol. 2018;14(5):293–304.
   PubMedGoogle Scholar
• Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51(2):660–678.
   PubMed Web of Science ®Google Scholar
• Lindor KD, Kowdley KV, Harrison ME. ACG clinical guideline: primary sclerosing cholangitis. Am J Gastroenterol. 2015;110(5):646–659;quiz 660.
   Web of Science ®Google Scholar
• Martin P, DiMartini A, Feng S, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the study of liver diseases and the american society of transplantation. Hepatology. 2014;59(3):1144–1165.
   PubMed Web of Science ®Google Scholar
• Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Rev Gastroenterol Hepatol. 2006;3(6):318–328.
   Google Scholar
• Tabibian JH, Lindor KD. Primary sclerosing cholangitis: a review and update on therapeutic developments. Expert Rev Gastroenterol Hepatol. 2013;7(2):103–114.
   PubMed Web of Science ®Google Scholar
• Tabibian JH, O’Hara SP, Trussoni CE, et al. Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis. Hepatology. 2016;63(1):185–196.
   PubMed Web of Science ®Google Scholar
• Trussoni CE, Tabibian JH, Splinter PL, et al. Lipopolysaccharide (LPS)-induced biliary epithelial cell NRas activation requires epidermal growth factor receptor (EGFR). PloS One. 2015;10(4):e0125793.
   PubMed Web of Science ®Google Scholar
• Bergquist A, Montgomery SM, Bahmanyar S, et al. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2008;6(8):939–943.
   PubMed Web of Science ®Google Scholar
• Karlsen TH, Franke A, Melum E, et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology. 2010;138(3):1102–1111.
   PubMed Web of Science ®Google Scholar
• Trivedi PJ, Adams DH. Mucosal immunity in liver autoimmunity: a comprehensive review. J Autoimmun. 2013;46:97–111.
   PubMed Web of Science ®Google Scholar
• Mederacke I, Hsu CC, Troeger JS, et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun. 2013;4:2823.
   PubMed Web of Science ®Google Scholar
• Dyson JK, Beuers U, Jones DEJ, et al. Primary sclerosing cholangitis. Lancet. 2018;391(10139):2547–2559.
   PubMed Web of Science ®Google Scholar
• Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology. 2002;36(3):525–531.
   PubMed Web of Science ®Google Scholar
• Beuers U, Spengler U, Kruis W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology. 1992;16(3):707–714.
   PubMed Web of Science ®Google Scholar
• Olsson R, Boberg KM, de Muckadell OS, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology. 2005;129(5):1464–1472.
   PubMed Web of Science ®Google Scholar
• Lindor KD, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50(3):808–814.
   PubMed Web of Science ®Google Scholar
• Imam MH, Sinakos E, Gossard AA, et al. High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. Aliment Pharmacol Ther. 2011;34(10):1185–1192.
   PubMed Web of Science ®Google Scholar
• Brandsaeter B, Isoniemi H, Broome U, et al. Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol. 2004;40(5):815–822.
   PubMed Web of Science ®Google Scholar
• Ashraf I, Choudhary A, Arif M, et al. Ursodeoxycholic acid in patients with ulcerative colitis and primary sclerosing cholangitis for prevention of colon cancer: a meta-analysis. Indian J Gastroenterol. 2012;31(2):69–74.
   PubMedGoogle Scholar
• Wunsch E, Trottier J, Milkiewicz M, et al. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. Hepatology. 2014;60(3):931–940.
   PubMed Web of Science ®Google Scholar
• Othman MO, Dunkelberg J, Roy PK. Urosdeoxycholic acid in primary sclerosing cholangitis: a meta-analysis and systematic review. Arab J Gastroenterol. 2012;13(3):103–110.
   PubMedGoogle Scholar
• Triantos CK, Koukias NM, Nikolopoulou VN, et al. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis. Aliment Pharmacol Ther. 2011;34(8):901–910.
   PubMed Web of Science ®Google Scholar
• Datta DV, Sherlock S. Treatment of pruritus of obstructive jaundice with cholestyramine. Br Med J. 1963;1(5325):216–219.
   PubMedGoogle Scholar
• EASL Clinical Practice. Guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51(2):237–267.
   PubMed Web of Science ®Google Scholar
• Mells GF, Pells G, Newton JL, et al. Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study. Hepatology. 2013;58(1):273–283.
   PubMed Web of Science ®Google Scholar
• Trivedi HD, Lizaola B, Tapper EB, et al. Management of pruritus in primary biliary cholangitis: a narrative review. Am J Med. 2017;130(6):744.e741–744.e747.
   Web of Science ®Google Scholar
• Angulo P, Grandison GA, Fong DG, et al. Bone disease in patients with primary sclerosing cholangitis. Gastroenterology. 2011;140(1):180–188.
   PubMed Web of Science ®Google Scholar
• Danford CJ, Trivedi HD, Bonder A. Bone health in patients with liver diseases. J Clin Densitom. 2019. Doi: https://doi.org/10.1016/j.jocd.2019.01.004.
   Google Scholar
• Collier J. Bone disorders in chronic liver disease. Hepatology. 2007;46(4):1271–1278.
   PubMed Web of Science ®Google Scholar
• Zein CO, Jorgensen RA, Clarke B, et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology. 2005;42(4):762–771.
   PubMed Web of Science ®Google Scholar
• Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375(7):631–643.
   PubMed Web of Science ®Google Scholar
• Larusso N, Bowlus C, Levy C, et al. PC. 01.8 the aesop trial: a randomized, double-blind, placebo-controlled, phase 2 study of obeticholic acid in patients with primary sclerosing cholangitis. a randomized, double-blind, placebo-controlled, phase 2 study of obeticholic acid in patients with primary sclerosing cholangitis. 2018;50(2):e67 Larusso N, Bowlus C, Levy C, et al. PC. 01.8 the aesop trial: a randomized, double-blind, placebo-controlled, phase 2 study of obeticholic acid in patients with primary sclerosing cholangitis. a randomized, double-blind, placebo-controlled, phase 2 study of obeticholic acid in patients with primary sclerosing cholangitis. Digestive and Liver Disease. 2018;50(2):e67.
   Google Scholar
• Tabibian JH, Weeding E, Jorgensen RA, et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther. 2013;37(6):604–612.
   PubMed Web of Science ®Google Scholar
• Farkkila M, Karvonen AL, Nurmi H, et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology. 2004;40(6):1379–1386.
   PubMed Web of Science ®Google Scholar
• Silveira MG, Torok NJ, Gossard AA, et al. Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study. Am J Gastroenterol. 2008;104:83.
   Web of Science ®Google Scholar
• Hofmann AF, Zakko SF, Lira M, et al. Novel biotransformation and physiological properties of norursodeoxycholic acid in humans. Hepatology. 2005;42(6):1391–1398.
   PubMed Web of Science ®Google Scholar
• Fickert P, Pollheimer MJ, Silbert D, et al. Differential effects of norUDCA and UDCA in obstructive cholestasis in mice. J Hepatol. 2013;58(6):1201–1208.
   PubMed Web of Science ®Google Scholar
• Fickert P, Hirschfield GM, Denk G, et al. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J Hepatol. 2017;67(3):549–558.
   PubMed Web of Science ®Google Scholar
• Shoda J, Okada K, Inada Y, et al. Bezafibrate induces multidrug-resistance P-Glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice. Hepatol Res. 2007;37(7):548–556.
   PubMed Web of Science ®Google Scholar
• Inoue I, Noji S, Awata T, et al. Bezafibrate has an antioxidant effect: peroxisome proliferator-activated receptor alpha is associated with Cu2+, Zn2+-superoxide dismutase in the liver. Life Sci. 1998;63(2):135–144.
   PubMed Web of Science ®Google Scholar
• Hirano F, Kobayashi A, Makino I. Inhibition of TNF-alpha-induced RANTES expression in human hepatocyte-derived cells by fibrates, the hypolipidemic drugs. Int Immunopharmacol. 2003;3(2):225–232.
   PubMed Web of Science ®Google Scholar
• Mizuno S, Hirano K, Isayama H, et al. Prospective study of bezafibrate for the treatment of primary sclerosing cholangitis. J Hepatobiliary Pancreat Sci. 2015;22(10):766–770.
   PubMed Web of Science ®Google Scholar
• Dejman A, Clark V, Martin P, et al. Fenofibrate improves alkaline phosphatase in primary sclerosing cholangitis. Hepatology. 2013;144(5, Supplement 1):S1028–S1029.
   Google Scholar
• Lemoinne S, Pares A, Reig A, et al. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: french-Spanish experience. Clin Res Hepatol Gastroenterol. 2018;42(6):521–528.
   PubMed Web of Science ®Google Scholar
• Christensen B, Micic D, Gibson PR, et al. Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Aliment Pharmacol Ther. 2018;47(6):753–762.
   PubMed Web of Science ®Google Scholar
• Muir A, Goodman Z, Levy C, et al. Efficacy and safety of simtuzumab for the treatment of primary sclerosing cholangitis: results of a phase 2b, dose-ranging, randomized, placebo-controlled trial. 2017;66(1):S73 uir A, Goodman Z, Levy C, et al. Efficacy and safety of simtuzumab for the treatment of primary sclerosing cholangitis: results of a phase 2b, dose-ranging, randomized, placebo-controlled trial. Journal of Hepatology. 2017;66(1):S73.
   Google Scholar
• Muir AJ, Levy C, Janssen HL, et al. Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease. Hepatology. 2019;69(2):684–698.
   PubMed Web of Science ®Google Scholar